Point cloud fusion instance effect. حسب Hongliang Zou (20707270)

الموضوعات:

ActAs and CoT prompt strategies do not result in decreased error rate for tasks with increasing complexity. حسب Jacqueline A. Jansen (14894276)

Self-correction prompt strategy results in decreased error rate for all tasks with increasing complexity. حسب Jacqueline A. Jansen (14894276)

fileCont prompt strategy results in decreased error rate for some tasks with increasing complexity. حسب Jacqueline A. Jansen (14894276)

Schematic diagram of time stamp synchronization between LIDAR and camera in a multi-sensor system. حسب Hongliang Zou (20707270)

الموضوعات:

System architecture for localization and scene reconstruction methods in autonomous navigation of RD based on multi-sensor multi-level fusion. حسب Hongliang Zou (20707270)

الموضوعات:

Thematic clouds for lectures. حسب Ignacio García-Espona (21395335)

The result of the deviation of the angle axis between the RD and the three-dimensional point cloud coordinates during the actual movement process. حسب Hongliang Zou (20707270)

الموضوعات:

The number of COVID-19 patients admitted to the health system during the pandemic with the timing of data collection for the 2 study phases. حسب Elie Mulhem (22537863)

الموضوعات:

Displacement cloud maps. حسب Maogang Tian (21485116)

الموضوعات:

GPT-4 results in decreased error rate for all tasks with increasing complexity when compared to GPT-3.5-turbo. حسب Jacqueline A. Jansen (14894276)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Thematic cloud for posters [2013-23]. حسب Ignacio García-Espona (21395335)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات: